25.54

5.84% 1.41

After Hours: 25.25 -0.29 -1.14%

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $25.54, with a volume of 824.09K. It is up +5.84% in the last 24 hours and up +16.73% over the past month. Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Previous Close:

$24.13

Open:

$24

24h Volume:

824.09K

Relative Volume:

3.40

Market Cap:

$1.20B

Revenue:

Net Income/Loss:

$-71.58M

P/E Ratio:

-20.58

EPS:

-1.2413

Net Cash Flow:

$-61.42M

1W Performance:

+8.36%

1M Performance:

+16.73%

6M Performance:

+45.20%

1Y Performance:

+86.97%

1-Day Range:

$23.78

$25.61

1-Week Range:

$22.81

$25.61

52-Week Range:

$9.80

$27.67

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

ELVN's Discussions on Twitter

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

05:25 AM

Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial - Clinical Trials Arena

05:25 AM

04:52 AM

Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial - Yahoo Finance

04:52 AM

Sep 29, 2024

Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going - MSN

Sep 29, 2024

Sep 28, 2024

Enliven Therapeutics Announces Positive Data Update from - GlobeNewswire

Sep 28, 2024

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - GlobeNewswire Inc.

Sep 28, 2024

Sep 26, 2024

Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going - Yahoo Finance

Sep 26, 2024

Sep 24, 2024

ProShare Advisors LLC Purchases 5,372 Shares of Aon plc (NYSE:AON) - Defense World

Sep 24, 2024

67,600 Shares in The AZEK Company Inc. (NYSE:AZEK) Purchased by Appian Way Asset Management LP - Defense World

Sep 24, 2024

Logos Global Management LP Acquires New Shares in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Sep 24, 2024

ESAB Co. (NYSE:ESAB) Stock Position Cut by Front Street Capital Management Inc. - Defense World

Sep 24, 2024

Logos Global Management LP Trims Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Sep 24, 2024

Sep 23, 2024

Analyzing Enliven Therapeutics Inc (ELVN) After Recent Trading Activity - Knox Daily

Sep 23, 2024

Perhaps timely catching Enliven Therapeutics Inc (ELVN) would be a good idea - SETE News

Sep 23, 2024

HighVista Strategies LLC Reduces Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Sep 23, 2024

Sep 21, 2024

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 8.3% - Defense World

Sep 21, 2024

Sep 20, 2024

Quest Partners LLC Has $37,000 Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Sep 20, 2024

Sep 19, 2024

Enliven Therapeutics (NASDAQ:ELVN) Trading Up 8.3% - MarketBeat

Sep 19, 2024

(ELVN) Proactive Strategies - Stock Traders Daily

Sep 19, 2024

Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Australia

Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com South Africa

Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada

Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock - Investing.com India

Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock - Investing.com

Sep 18, 2024

Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com UK

Sep 18, 2024

Enliven Therapeutics Announces Details Regarding the - GlobeNewswire

Sep 18, 2024

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - StockTitan

Sep 18, 2024

Enlight Renewable Energy (NASDAQ:ENLT) Trading Up 3.8% - MarketBeat

Sep 18, 2024

Enlight Renewable Energy (NASDAQ:ENLT) Shares Gap Down to $16.73 - Defense World

Sep 18, 2024

Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc.ENFN - PR Newswire

Sep 17, 2024

Sep 16, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Bank of New York Mellon Corp - MarketBeat

Sep 16, 2024

Sep 13, 2024

First Turn Management LLC Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Sep 13, 2024

Sep 12, 2024

Wharton San Diego Presents: The Future of Biotechnology in San Diego - Procopio

Sep 12, 2024

Enliven Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of ($0.46) Per Share (NASDAQ:ELVN) - Defense World

Sep 12, 2024

Sep 11, 2024